# A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

> **NCT03238963** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 79 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** BI 1467335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03238963
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2020-05-14
- **Final completion:** 2020-05-14
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238963, "A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03238963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*